Adverse Consequences of Co-Occurring Opioid Use Disorder and Cannabis Use Disorder Compared to Opioid Use Disorder Only

References

• Rudd RA Increases in drug and opioid-involved overdose deaths – United States, 2010–2015. MMWR. Morbidity and mortality weekly report; 2016, 65.
   Google Scholar
• Hill KP, Saxon AJ. The role of cannabis legalization in the opioid crisis. JAMA Intern Med. 2018;178(5):679–80. doi:10.1001/jamainternmed.2018.0254.
   PubMed Web of Science ®Google Scholar
• Gupta S Why I changed my mind on weed. CNN. com 2013; 9.
   Google Scholar
• Bachhuber MA, Saloner B, Cunningham CO, Barry CL. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. JAMA Intern Med. 2014;174(10):1668–73. doi:10.1001/jamainternmed.2014.4005.
   PubMed Web of Science ®Google Scholar
• Powell D, Pacula RL, Jacobson M. Do medical marijuana laws reduce addictions and deaths related to pain killers? J Health Econ. 2018;58:29–42. doi:10.1016/j.jhealeco.2017.12.007.
   PubMed Web of Science ®Google Scholar
• Boehnke KF, Litinas E, Clauw DJ. Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. J Pain. 2016;17(6):739–44. doi:10.1016/j.jpain.2016.03.002.
   PubMed Web of Science ®Google Scholar
• Corroon JM Jr, Mischley LK, Sexton M. Cannabis as a substitute for prescription drugs – a cross-sectional study. J Pain Res. 2017;10:989. doi:10.2147/JPR.S134133.
   PubMed Web of Science ®Google Scholar
• Reiman A, Welty M, Solomon P. Cannabis as a substitute for opioid-based pain medication: patient self-report. Cannabis Cannabinoid Res. 2017;2(1):160–66. doi:10.1089/can.2017.0012.
   PubMedGoogle Scholar
• Sexton M, Cuttler C, Finnell JS, Mischley LK. A cross-sectional survey of medical cannabis users: patterns of use and perceived efficacy. Cannabis Cannabinoid Res. 2016;1(1):131–38. doi:10.1089/can.2016.0007.
   PubMedGoogle Scholar
• Bradford AC, Bradford WD. Medical marijuana laws reduce prescription medication use in Medicare Part D. Health Aff. 2016;35(7):1230–36. doi:10.1377/hlthaff.2015.1661.
   PubMed Web of Science ®Google Scholar
• Bradford AC, Bradford WD. Medical marijuana laws may be associated with a decline in the number of prescriptions for Medicaid enrollees. Health Aff. 2017;36(5):945–51. doi:10.1377/hlthaff.2016.1135.
   Web of Science ®Google Scholar
• Kim JH, Santaella-Tenorio J, Mauro C, Wrobel J, Cerdà M, Keyes KM, Hasin D, Martins SS, Li G. State medical marijuana laws and the prevalence of opioids detected among fatally injured drivers. Am J Public Health. 2016;106(11):2032–37. doi:10.2105/AJPH.2016.303426.
   PubMed Web of Science ®Google Scholar
• Shi Y. Medical marijuana policies and hospitalizations related to marijuana and opioid pain reliever. Drug Alcohol Depend. 2017;173:144–50. doi:10.1016/j.drugalcdep.2017.01.006.
   PubMed Web of Science ®Google Scholar
• Cerdá M, Wall M, Keyes KM, Galea S, Hasin D. Medical marijuana laws in 50 states: investigating the relationship between state legalization of medical marijuana and marijuana use, abuse and dependence. Drug Alcohol Depend. 2012;120(1):22–27. doi:10.1016/j.drugalcdep.2011.06.011.
   PubMed Web of Science ®Google Scholar
• Ahrnsbrak R, Bose J, Hedden S, Lipari R, Park-Lee E. Key substance use and mental health indicators in the United States: results from the 2016 National Survey on Drug Use and Health. Rockville, MD, USA: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2017.
   Google Scholar
• Scavone J, Sterling R, Van Bockstaele E. Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. Neuroscience. 2013;248:637–54. doi:10.1016/j.neuroscience.2013.04.034.
   PubMed Web of Science ®Google Scholar
• Cooper ZD, Bedi G, Ramesh D, Balter R, Comer SD, Haney M. Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability. Neuropsychopharmacology. 2018;43(10):2046.
   Web of Science ®Google Scholar
• Bahorik AL, Satre DD, Kline-Simon AH, Weisner CM, Campbell CI. Alcohol, cannabis, and opioid use disorders, and disease burden in an integrated health care system. J Addict Med. 2017;11(1):3–9. doi:10.1097/ADM.0000000000000260.
   PubMed Web of Science ®Google Scholar
• Iheanacho T, Stefanovics E, Rosenheck R. Opioid use disorder and homelessness in the Veterans Health Administration: the challenge of multimorbidity. J Opioid Manag. 2018;14(3):171–82. doi:10.5055/jom.2018.0447.
   PubMedGoogle Scholar
• Imtiaz S, Shield KD, Roerecke M, Cheng J, Popova S, Kurdyak P, Fischer B, Rehm J. The burden of disease attributable to cannabis use in Canada in 2012. Addiction. 2016;111(4):653–62. doi:10.1111/add.13237.
   PubMed Web of Science ®Google Scholar
• Lachenmeier DW, Rehm J. Comparative risk assessment of alcohol, tobacco, cannabis and other illicit drugs using the margin of exposure approach. Sci Rep. 2015;5:8126. doi:10.1038/srep08126.
   PubMed Web of Science ®Google Scholar
• Perron BE, Bohnert K, Perone AK, Bonn-Miller MO, Ilgen M. Use of prescription pain medications among medical cannabis patients: comparisons of pain levels, functioning, and patterns of alcohol and other drug use. J Stud Alcohol Drugs. 2015;76(3):406–13.
   PubMed Web of Science ®Google Scholar
• Nielsen S, Sabioni P, Trigo JM, Ware MA, Betz-Stablein BD, Murnion B, Lintzeris N, Khor KE, Farrell M, Smith A. Opioid-sparing effect of cannabinoids: a systematic review and meta-analysis. Neuropsychopharmacology. 2017;42(9):1752. doi:10.1038/npp.2017.51.
   PubMed Web of Science ®Google Scholar
• Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Cannabis‐based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2018;3.
   Google Scholar
• Voelker R. States move to substitute opioids with medical marijuana to quell epidemic. JAMA. 2018. doi:10.1001/jama.2018.17329.
   Web of Science ®Google Scholar
• Morasco BJ, Gritzner S, Lewis L, Oldham R, Turk DC, Dobscha SK. Systematic review of prevalence, correlates, and treatment outcomes for chronic non-cancer pain in patients with comorbid substance use disorder. Pain®. 2011;152(3):488–97. doi:10.1016/j.pain.2010.10.009.
   PubMed Web of Science ®Google Scholar
• Fleming MF, Balousek SL, Klessig CL, Mundt MP, Brown DD. Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain. 2007;8(7):573–82. doi:10.1016/j.jpain.2007.02.432.
   PubMed Web of Science ®Google Scholar
• Morasco BJ, Dobscha SK. Prescription medication misuse and substance use disorder in VA primary care patients with chronic pain. Gen Hosp Psychiatry. 2008;30(2):93–99. doi:10.1016/j.genhosppsych.2007.12.004.
   PubMed Web of Science ®Google Scholar
• Bonn-Miller MO, Harris AH, Trafton JA. Prevalence of cannabis use disorder diagnoses among veterans in 2002, 2008, and 2009. Psychol Serv. 2012;9(4):404. doi:10.1037/a0026143.
   PubMed Web of Science ®Google Scholar
• Edlund MJ, Steffick D, Hudson T, Harris KM, Sullivan M. Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer pain. Pain. 2007;129(3):355–62. doi:10.1016/j.pain.2007.02.014.
   PubMed Web of Science ®Google Scholar
• Hall W, West R, Marsden J, Humphreys K, Neale J, Petry N. It is premature to expand access to medicinal cannabis in hopes of solving the US opioid crisis. Addiction. 2018;113(6):987–88. doi:10.1111/add.14139.
   PubMed Web of Science ®Google Scholar
• Eberhardt MS, Ingram DD, Makuc DM, Pamuk E, Freid V, Harper S, Schoenborn C, Xia H. Urban and rural health chartbook. Vol. 2001. Health United States, Department of Health and Human Services, Centers for Disease Control and Prevention; 2001.
   Google Scholar
• Edens EL, Kasprow W, Tsai J, Rosenheck RA. Association of substance use and VA service‐connected disability benefits with risk of homelessness among veterans. Am J Addict. 2011;20(5):412–19. doi:10.1111/j.1521-0391.2011.00166.x.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.
   PubMedGoogle Scholar
• Barry DT, Sofuoglu M, Kerns RD, Wiechers IR, Rosenheck RA. Prevalence and correlates of co-prescribing psychotropic medications with long-term opioid use nationally in the Veterans Health Administration. Psychiatry Res. 2015;227(2–3):324–32. doi:10.1016/j.psychres.2015.03.006.
   PubMed Web of Science ®Google Scholar
• Petrakis IL, Sofuoglu M, Rosenheck R. VA patients with high numbers of opioid prescriptions: A national study of sociodemographic and diagnostic characteristics, health service, and psychotropic medication use. Addict Disord Their Treat. 2015;14(4):167–75. doi:10.1097/ADT.0000000000000058.
   Web of Science ®Google Scholar
• Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, New Jersey: L. Erlbaum; 1988.
   Google Scholar
• Olfson M, Wall MM, Liu S-M, Blanco C. Cannabis use and risk of prescription opioid use disorder in the United States. Am J Psychiatry. 2017;175(1):47–53. doi:10.1176/appi.ajp.2017.17040413.
   PubMed Web of Science ®Google Scholar
• Merlin JS, Long D, Becker WC, Cachay ER, Christopolous KA, Claborn KR, Crane HM, Edelman EJ, Lovejoy TI, Mathews WC. Marijuana use is not associated with changes in opioid prescriptions or pain severity among people living with hiv and chronic pain. JAIDS J Acquir Immune Defic Syndr. 2019. doi:10.1097/QAI.0000000000001998.
   PubMed Web of Science ®Google Scholar
• Kessler RC. The epidemiology of dual diagnosis. Biol Psychiatry. 2004;56(10):730–37. doi:10.1016/j.biopsych.2004.06.034.
   PubMed Web of Science ®Google Scholar
• Liu Y, Williamson V, Setlow B, Cottler LB, Knackstedt LA. The importance of considering polysubstance use: lessons from cocaine research. Drug Alcohol Depend. 2018. doi:10.1016/j.drugalcdep.2018.07.025.
   Web of Science ®Google Scholar
• Mertens JR, Lu YW, Parthasarathy S, Moore C, Weisner CM. Medical and psychiatric conditions of alcohol and drug treatment patients in an HMO: comparison with matched controls. Arch Intern Med. 2003;163(20):2511–17. doi:10.1001/archinte.163.20.2511.
   PubMed Web of Science ®Google Scholar
• Bhalla IP, Stefanovics EA, Rosenheck RA. Clinical epidemiology of single versus multiple substance use disorders: polysubstance use disorder. Med Care. 2017;55:S24–S32. doi:10.1097/MLR.0000000000000731.
   PubMed Web of Science ®Google Scholar
• Bhalla I SEaRR. Polysubstance use among veterans treated in specialized intensive veterans health administration PTSD programs: impact on symptoms and outcomes following treatment. J Dual Diagn. (in press). 2018:1–10.
   Google Scholar
• Lembke A, Humphreys K, Newmark J. Weighing the risks and benefits of chronic opioid therapy. Am Fam Physician. 2016;93:12.
   Web of Science ®Google Scholar
• McClure EA, King JS, Wahle A, Matthews AG, Sonne SC, Lofwall MR, McRae-Clark AL, Ghitza UE, Martinez M, Cloud K. Comparing adult cannabis treatment-seekers enrolled in a clinical trial with national samples of cannabis users in the United States. Drug Alcohol Depend. 2017;176:14–20. doi:10.1016/j.drugalcdep.2017.02.024.
   PubMed Web of Science ®Google Scholar
• De Aquino JP, Sherif M, Radhakrishnan R, Cahill JD, Ranganathan M, D’Souza DC. The psychiatric consequences of cannabinoids. Clin Ther. 2018. doi:10.1016/j.clinthera.2018.03.013.
   PubMed Web of Science ®Google Scholar
• Webster LR. Risk factors for opioid-use disorder and overdose. Anesth Analg. 2017;125(5):1741–48. doi:10.1213/ANE.0000000000002496.
   PubMed Web of Science ®Google Scholar
• Martins SS, Keyes KM, Storr CL, Zhu H, Chilcoat HD. Pathways between nonmedical opioid use/dependence and psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend. 2009;103(1–2):16–24. doi:10.1016/j.drugalcdep.2009.01.019.
   PubMed Web of Science ®Google Scholar
• Conway KP, Compton W, Stinson FS, Grant BF. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2006;67(2):247–57.
   PubMed Web of Science ®Google Scholar
• Sullivan MD. Depression effects on long-term prescription opioid use, abuse, and addiction. Clin J Pain. 2018;34(9):878–84. doi:10.1097/AJP.0000000000000603.
   PubMed Web of Science ®Google Scholar
• Feingold D, Brill S, Goor-Aryeh I, Delayahu Y, Lev-Ran S. Depression and anxiety among chronic pain patients receiving prescription opioids and medical marijuana. J Affect Disord. 2017;218:1–7. doi:10.1016/j.jad.2017.04.026.
   PubMed Web of Science ®Google Scholar
• Scherrer JF, Salas J, Sullivan MD, Schneider FD, Bucholz KK, Burroughs T, Copeland L, Ahmedani B, Lustman PJ. The influence of prescription opioid use duration and dose on development of treatment resistant depression. Prev Med. 2016;91:110–16. doi:10.1016/j.ypmed.2016.08.003.
   PubMed Web of Science ®Google Scholar
• Scherrer JF, Salas J, Schneider FD, Bucholz KK, Sullivan MD, Copeland LA, Ahmedani BK, Burroughs T, Lustman PJ. Characteristics of new depression diagnoses in patients with and without prior chronic opioid use. J Affect Disord. 2017;210:125–29. doi:10.1016/j.jad.2016.12.027.
   PubMed Web of Science ®Google Scholar
• Leweke FM, Koethe D. Cannabis and psychiatric disorders: it is not only addiction. Addict Biol. 2008;13(2):264–75. doi:10.1111/j.1369-1600.2008.00106.x.
   PubMed Web of Science ®Google Scholar
• Large M, Sharma S, Compton MT, Slade T, Nielssen O. Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry. 2011;68(6):555–61. doi:10.1001/archgenpsychiatry.2011.5.
   PubMed Web of Science ®Google Scholar
• Starzer MSK, Nordentoft M, Hjorthøj C. Rates and predictors of conversion to schizophrenia or bipolar disorder following substance-induced psychosis. Am J Psychiatry. 2017;175(4):343–350.
   PubMed Web of Science ®Google Scholar
• Lev-Ran S, Roerecke M, Le Foll B, George TP, McKenzie K, Rehm J. The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. Psychol Med. 2014;44(4):797–810. doi:10.1017/S0033291713001438.
   PubMed Web of Science ®Google Scholar
• Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA, Marconi A, La Cascia C, Reis Marques T, Pariante C, et al. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull. 2014;40(6):1509–17. doi:10.1093/schbul/sbt181.
   PubMed Web of Science ®Google Scholar
• North CS, Brown ES, Pollio DE. Expanded conceptualization of multimorbidity to encompass substance use disorders and other psychiatric illness. Ann Clin Psychiatry. 2016;28(3):182–88.
   PubMed Web of Science ®Google Scholar
• Tinetti ME, Basu J. Research on multiple chronic conditions: where we are and where we need to go. LWW. 2014:S3–S6.
   Google Scholar
• Tinetti ME, Fried TR, Boyd CM. Designing health care for the most common chronic condition – multimorbidity. Jama. 2012;307(23):2493–94. doi:10.1001/jama.2012.5265.
   PubMed Web of Science ®Google Scholar
• Hartz SM, Horton AC, Oehlert M, Carey CE, Agrawal A, Bogdan R, Chen L-S, Hancock DB, Johnson EO, Pato CN. Association between substance use disorder and polygenic liability to schizophrenia. Biol Psychiatry. 2017;82(10):709–15. doi:10.1016/j.biopsych.2017.04.020.
   PubMed Web of Science ®Google Scholar
• Kristjansson S, McCutcheon VV, Agrawal A, Lynskey MT, Conroy E, Statham DJ, Madden PA, Henders AK, Todorov AA, Bucholz KK. The variance shared across forms of childhood trauma is strongly associated with liability for psychiatric and substance use disorders. Brain Behav. 2016;6(2):e00432. doi:10.1002/brb3.432.
   PubMed Web of Science ®Google Scholar
• MacLean RR, Sofuoglu M, Rosenheck R. Tobacco and alcohol use disorders: evaluating multimorbidity. Addict Behav. 2018;78:59–66. doi:10.1016/j.addbeh.2017.11.006.
   PubMed Web of Science ®Google Scholar
• Bhalla IP, Rosenheck RA. A change in perspective: from dual diagnosis to multimorbidity. Psychiatr Serv. 2017;69(1):112–16. doi:10.1176/appi.ps.201700194.
   PubMed Web of Science ®Google Scholar
• Hurd YL, Yoon M, Manini AF, Hernandez S, Olmedo R, Ostman M, Jutras-Aswad D. Early phase in the development of cannabidiol as a treatment for addiction: opioid relapse takes initial center stage. Neurotherapeutics. 2015;12(4):807–15. doi:10.1007/s13311-015-0373-7.
   PubMed Web of Science ®Google Scholar
• Kral AH, Wenger L, Novak SP, Chu D, Corsi KF, Coffa D, Shapiro B, Bluthenthal RN. Is cannabis use associated with less opioid use among people who inject drugs? Drug Alcohol Depend. 2015;153:236–41. doi:10.1016/j.drugalcdep.2015.05.014.
   PubMed Web of Science ®Google Scholar
• Bagra I, Krishnan V, Rao R, Agrawal A. Does cannabis use influence opioid outcomes and quality of life among buprenorphine maintained patients? A cross-sectional, comparative study. J Addict Med. 2018;12(4):315–20. doi:10.1097/ADM.0000000000000406.
   PubMed Web of Science ®Google Scholar
• Hill KP, Bennett HE, Griffin ML, Connery HS, Fitzmaurice GM, Subramaniam G, Woody GE, Weiss RD. Association of cannabis use with opioid outcomes among opioid-dependent youth. Drug Alcohol Depend. 2013;132(1–2):342–45. doi:10.1016/j.drugalcdep.2013.02.030.
   PubMed Web of Science ®Google Scholar
• Weizman T, Gelkopf M, Melamed Y, Adelson M, Bleich A. Cannabis abuse is not a risk factor for treatment outcome in methadone maintenance treatment: a 1-year prospective study in an Israeli clinic. Aust N Z J Psychiatry. 2004;38(1–2):42–46. doi:10.1046/j.1440-1614.2003.01296.x.
   PubMed Web of Science ®Google Scholar
• Franklyn AM, Eibl JK, Gauthier GJ, Marsh DC. The impact of cannabis use on patients enrolled in opioid agonist therapy in Ontario, Canada. PLoS One. 2017;12(11):e0187633. doi:10.1371/journal.pone.0187633.
   PubMed Web of Science ®Google Scholar
• Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, Jacobs P, Teruya C, McLaughlin P, Wiest K. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi‐site trial. Addiction. 2014;109(1):79–87. doi:10.1111/add.12333.
   PubMed Web of Science ®Google Scholar
• Socías ME, Wood E, Lake S, Nolan S, Fairbairn N, Hayashi K, Shulha HP, Liu S, Kerr T, Milloy MJ. High‐intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis. Addiction. 2018. doi:10.1111/add.14398.
   PubMed Web of Science ®Google Scholar
• Wiese B, Wilson-Poe AR. Emerging evidence for cannabis‘ role in opioid use disorder. Cannabis Cannabinoid Res. 2018;3(1):179–89. doi:10.1089/can.2018.0022.
   PubMedGoogle Scholar
• Browne KC, Dolan M, Simpson TL, Fortney JC, Lehavot K. Regular past year cannabis use in women veterans and associations with sexual trauma. Addict Behav. 2018;84:144–50. doi:10.1016/j.addbeh.2018.04.007.
   PubMed Web of Science ®Google Scholar
• Rincon HG, Granados M, Unutzer J, Gomez M, Duran R, Badiel M, Salas C, Martinez J, Mejia J, Ordoñez C. Prevalence, detection and treatment of anxiety, depression, and delirium in the adult critical care unit. Psychosomatics. 2001;42(5):391–96. doi:10.1176/appi.psy.42.5.391.
   PubMed Web of Science ®Google Scholar